Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges.
10.1097/CM9.0000000000001610
- VernacularTitle:Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges
- Author:
Chu-Ling LI
1
;
Yong SONG
Author Information
1. Department of Respiratory Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, Jiangsu 210000, China.
- Publication Type:Journal Article
- MeSH:
Angiogenesis Inhibitors/therapeutic use*;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Humans;
Immunotherapy;
Lung Neoplasms/drug therapy*;
Protein Kinase Inhibitors/therapeutic use*
- From:
Chinese Medical Journal
2021;134(16):1908-1919
- CountryChina
- Language:English
-
Abstract:
Immunotherapy has dramatically altered the treatment of non-small cell lung cancer. Currently, the emergence of combination strategies in immunotherapy has brightened the prospects of improved clinical outcomes and manageable safety profiles in the first/second-line settings. However, sub-optimal response rates are still observed in several clinical trials. Hence, alternative combination models and candidate selection strategies need to be explored. Herein, we have critically reviewed and commented on the published data from several clinical trials, including combined immunotherapy and chemotherapy, anti-angiogenic agents, epidermal growth factor receptor/anaplastic lymphoma kinase tyrosine kinase inhibitors, radiotherapy, and other immune checkpoint inhibitors.
